| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1999;68:2089-2092
© 1999 The Society of Thoracic Surgeons
a Section of Cardiac Surgery, University of Michigan Hospitals, Ann Arbor, Michigan, USA
Address reprint requests to Dr Bolling, Section of Cardiac Surgery, University of Michigan Hospitals, 1500 E Medical Center Dr, 2120D Taubman Center, Box 0344, Ann Arbor, MI 48109-0344;
e-mail: sbolling{at}umich.edu
Presented at the Thirty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 25–27, 1999.
Background. Cardiac surgery continues to be limited by an inability to achieve complete myocardial protection. This may result from the use of hypothermic cardioplegia. Interestingly, the subcellular changes of animal hibernation parallel the altered biology of induced hypothermic myocardial ischemia, but are well tolerated by hibernated mammalian myocardium. Evidence indicates this protection is mediated by activation of the delta opioid receptor, which elicits profound metabolic effects at the whole animal, organ, and cell level. In this study, we sought to determine if pentazocine, with agonist activity at the delta opioid receptor, could improve myocardial recovery following global ischemia over a wide range of temperatures.
Methods. Isolated rabbit hearts received either standard cardioplegia or were pretreated with racemic, d or l isomer pentazocine. Hearts were then subjected to 2 hours at 34°C, or 3.5 hours at 20°C, or 4 hours at 10°C of cardioplegic ischemia and reperfused. Functional recovery was compared to controls.
Results. Isovolumic developed pressure, coronary flow, oxygen consumption, and ultrastructural preservation were enhanced with pentazocine delta opioid mediated protection, which appears to be additive to standard cardioplegia, even at low temperatures.
Conclusions. Teleologically, delta opioid protection parallels animal hibernation, which occurs from 34° down to 0°C. The use of delta opioid receptor agonists may have important clinical implications for cardiac surgery and deserves further study.
This article has been cited by other articles:
|
|
 |
|
  W. B. Dobkowski Myocardial Protection During Minimally Invasive Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2002; 6(4): 319 - 324. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Kato and P. Foex Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists: [La protection myocardique contre les lesions d'ischemie-reperfusion par des anesthesiques : une mise a jour pour les anesthesiologistes] Can J Anesth, October 1, 2002; 49(8): 777 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Becker, M. L. Weisfeldt, M. H. Weil, T. Budinger, J. Carrico, K. Kern, G. Nichol, I. Shechter, R. Traystman, C. Webb, et al. The PULSE Initiative: Scientific Priorities and Strategic Planning for Resuscitation Research and Life Saving Therapies Circulation, May 28, 2002; 105(21): 2562 - 2570. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Karck, S. Tanaka, S. F. Bolling, A. Simon, T.-P. Su, P. R. Oeltgen, and A. Haverich Myocardial protection by ischemic preconditioning and {delta}-opioid receptor activation in the isolated working rat heart J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 986 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Sigg, J. A. Coles Jr, W. J. Gallagher, P. R. Oeltgen, and P. A. Iaizzo Opioid preconditioning: myocardial function and energy metabolism Ann. Thorac. Surg., November 1, 2001; 72(5): 1576 - 1582. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
